{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:47:36Z","timestamp":1782179256809,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972617"],"award-info":[{"award-number":["81972617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373371"],"award-info":[{"award-number":["82373371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10070-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:18:45Z","timestamp":1776860325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-1766","authenticated-orcid":false,"given":"Di","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-5164","authenticated-orcid":false,"given":"Jie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-9634","authenticated-orcid":false,"given":"Chunyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"10070_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10070_CR2","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni, F. et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184, 3998\u20134015.e3919 (2021).","journal-title":"Cell"},{"key":"10070_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).","journal-title":"Mol. Cancer"},{"key":"10070_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger, D. S. et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 20, 497\u2013530 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10070_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro, A., Brahmer, J., Antonia, S., Mok, T. & Peters, S. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J. Clin. Oncol. 40, 598\u2013610 (2022).","journal-title":"J. Clin. Oncol."},{"key":"10070_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews, L. P., Marciscano, A. E., Drake, C. G. & Vignali, D. A. LAG3 (CD223) as a cancer immunotherapy target. Immunol. Rev. 276, 80\u201396 (2017).","journal-title":"Immunol. Rev."},{"key":"10070_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell 176, 334\u2013347.e312 (2019).","journal-title":"Cell"},{"key":"10070_CR8","doi-asserted-by":"publisher","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2021","unstructured":"Shi, A. P. et al. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Front Immunol. 12, 785091 (2021).","journal-title":"Front Immunol."},{"key":"10070_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","volume":"14","author":"W Qian","year":"2021","unstructured":"Qian, W., Zhao, M., Wang, R. & Li, H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J. Hematol. Oncol. 14, 147 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"10070_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/cei\/uxad137","volume":"216","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response. Clin. Exp. Immunol. 216, 68\u201379 (2024).","journal-title":"Clin. Exp. Immunol."},{"key":"10070_CR11","doi-asserted-by":"publisher","first-page":"e164528","DOI":"10.1172\/JCI164528","volume":"133","author":"M Lin","year":"2023","unstructured":"Lin, M. et al. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. J. Clin. Invest 133, e164528 (2023).","journal-title":"J. Clin. Invest"},{"key":"10070_CR12","doi-asserted-by":"publisher","first-page":"738473","DOI":"10.3389\/fimmu.2021.738473","volume":"12","author":"EL Jones","year":"2021","unstructured":"Jones, E. L., Laidlaw, S. M. & Dustin, L. B. TRIM21\/Ro52 - Roles in Innate Immunity and Autoimmune Disease. Front Immunol. 12, 738473 (2021).","journal-title":"Front Immunol."},{"key":"10070_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03143-x","volume":"23","author":"CH Hsu","year":"2023","unstructured":"Hsu, C. H. & Yu, Y. L. The interconnected roles of TRIM21\/Ro52 in systemic lupus erythematosus, primary Sj\u00f6gren\u2019s syndrome, cancers, and cancer metabolism. Cancer Cell Int. 23, 289 (2023).","journal-title":"Cancer Cell Int"},{"key":"10070_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105443","volume":"165","author":"M Alomari","year":"2021","unstructured":"Alomari, M. TRIM21 - A potential novel therapeutic target in cancer. Pharm. Res. 165, 105443 (2021).","journal-title":"Pharm. Res"},{"key":"10070_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13046-022-02583-z","volume":"42","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. TRIM21 attenuates renal carcinoma lipogenesis and malignancy by regulating SREBF1 protein stability. J. Exp. Clin. Cancer Res. 42, 34 (2023).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10070_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05944-4","volume":"14","author":"C Xu","year":"2023","unstructured":"Xu, C. et al. BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1. Cell Death Dis. 14, 445 (2023).","journal-title":"Cell Death Dis."},{"key":"10070_CR17","doi-asserted-by":"publisher","first-page":"e164354","DOI":"10.1172\/JCI164354","volume":"133","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer. J. Clin. Invest 133, e164354 (2023).","journal-title":"J. Clin. Invest"},{"key":"10070_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/107999002753452610","volume":"22","author":"A Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger, A., K\u00f6ster, M., Schroeder, K., Hauser, H. & Mueller, P. P. Activities of IRF-1. J. Interferon Cytokine Res. 22, 5\u201314 (2002).","journal-title":"J. Interferon Cytokine Res"},{"key":"10070_CR19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/35636","volume":"391","author":"K Ogasawara","year":"1998","unstructured":"Ogasawara, K. et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391, 700\u2013703 (1998).","journal-title":"Nature"},{"key":"10070_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1146\/annurev.immunol.19.1.623","volume":"19","author":"T Taniguchi","year":"2001","unstructured":"Taniguchi, T., Ogasawara, K., Takaoka, A. & Tanaka, N. IRF family of transcription factors as regulators of host defense. Annu Rev. Immunol. 19, 623\u2013655 (2001).","journal-title":"Annu Rev. Immunol."},{"key":"10070_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","volume":"51","author":"A Forero","year":"2019","unstructured":"Forero, A. et al. Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons. Immunity 51, 451\u2013464.e456 (2019).","journal-title":"Immunity"},{"key":"10070_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009220","volume":"17","author":"H Feng","year":"2021","unstructured":"Feng, H., Zhang, Y. B., Gui, J. F., Lemon, S. M. & Yamane, D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog. 17, e1009220 (2021).","journal-title":"PLoS Pathog."},{"key":"10070_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"10070_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01963-6","volume":"22","author":"T S\u00e6varsson","year":"2024","unstructured":"S\u00e6varsson, T. et al. Differentiation status determines the effects of IFN\u03b3 on the expression of PD-L1 and immunomodulatory genes in melanoma. Cell Commun. Signal 22, 618 (2024).","journal-title":"Cell Commun. Signal"},{"key":"10070_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41420-024-02019-x","volume":"10","author":"H Shi","year":"2024","unstructured":"Shi, H. et al. Nur77-IRF1 axis inhibits esophageal squamous cell carcinoma growth and improves anti-PD-1 treatment efficacy. Cell Death Discov. 10, 254 (2024).","journal-title":"Cell Death Discov."},{"key":"10070_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113362","volume":"42","author":"T Tian","year":"2023","unstructured":"Tian, T. et al. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Rep. 42, 113362 (2023).","journal-title":"Cell Rep."},{"key":"10070_CR27","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3389\/fimmu.2019.02049","volume":"10","author":"S Foss","year":"2019","unstructured":"Foss, S. et al. TRIM21-From Intracellular Immunity to Therapy. Front Immunol. 10, 2049 (2019).","journal-title":"Front Immunol."},{"key":"10070_CR28","doi-asserted-by":"publisher","first-page":"e32660","DOI":"10.7554\/eLife.32660","volume":"7","author":"C Dickson","year":"2018","unstructured":"Dickson, C. et al. Intracellular antibody signalling is regulated by phosphorylation of the Fc receptor TRIM21. Elife 7, e32660 (2018).","journal-title":"Elife"},{"key":"10070_CR29","doi-asserted-by":"publisher","first-page":"bbab574","DOI":"10.1093\/bib\/bbab574","volume":"23","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. GPS-Uber: a hybrid-learning framework for prediction of general and E3-specific lysine ubiquitination sites. Brief. Bioinform 23, bbab574 (2022).","journal-title":"Brief. Bioinform"},{"key":"10070_CR30","doi-asserted-by":"publisher","first-page":"D729","DOI":"10.1093\/nar\/gky1094","volume":"47","author":"R Zheng","year":"2019","unstructured":"Zheng, R. et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 47, D729\u2013d735 (2019).","journal-title":"Nucleic Acids Res"},{"key":"10070_CR31","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute, I. et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 52, D174\u2013d182 (2024).","journal-title":"Nucleic Acids Res"},{"key":"10070_CR32","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","volume":"10","author":"N Berdelle","year":"2011","unstructured":"Berdelle, N., Nikolova, T., Quiros, S., Efferth, T. & Kaina, B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells. Mol. Cancer Ther. 10, 2224\u20132233 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"10070_CR33","first-page":"2277","volume":"24","author":"NP Singh","year":"2004","unstructured":"Singh, N. P. & Lai, H. C. Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24, 2277\u20132280 (2004).","journal-title":"Anticancer Res"},{"key":"10070_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","volume":"27","author":"GQ Chen","year":"2020","unstructured":"Chen, G. Q. et al. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 27, 242\u2013254 (2020).","journal-title":"Cell Death Differ."},{"key":"10070_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.fob.2012.05.002","volume":"2","author":"Z Wang","year":"2012","unstructured":"Wang, Z., Hu, W., Zhang, J. L., Wu, X. H. & Zhou, H. J. Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity. FEBS Open Bio. 2, 103\u2013112 (2012).","journal-title":"FEBS Open Bio"},{"key":"10070_CR36","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41401-023-01079-6","volume":"44","author":"SA Kov\u00e1cs","year":"2023","unstructured":"Kov\u00e1cs, S. A., Fekete, J. T. & Gy\u0151rffy, B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharm. Sin. 44, 1879\u20131889 (2023).","journal-title":"Acta Pharm. Sin."},{"key":"10070_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"10070_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L., Li, Y., Tan, J., Xu, L. & Li, Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"10070_CR39","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi, T. et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity 55, 912\u2013924.e918 (2022).","journal-title":"Immunity"},{"key":"10070_CR40","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1128\/MCB.01630-05","volume":"26","author":"A Sabile","year":"2006","unstructured":"Sabile, A. et al. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol. Cell Biol. 26, 5994\u20136004 (2006).","journal-title":"Mol. Cell Biol."},{"key":"10070_CR41","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.molimm.2010.05.004","volume":"47","author":"M Niida","year":"2010","unstructured":"Niida, M., Tanaka, M. & Kamitani, T. Downregulation of active IKK beta by Ro52-mediated autophagy. Mol. Immunol. 47, 2378\u20132387 (2010).","journal-title":"Mol. Immunol."},{"key":"10070_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0022034520949486","volume":"100","author":"EC Mooney","year":"2021","unstructured":"Mooney, E. C. & Sahingur, S. E. The Ubiquitin System and A20: Implications in Health and Disease. J. Dent. Res. 100, 10\u201320 (2021).","journal-title":"J. Dent. Res"},{"key":"10070_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek, K. N. & Komander, D. Ubiquitin modifications. Cell Res 26, 399\u2013422 (2016).","journal-title":"Cell Res"},{"key":"10070_CR44","doi-asserted-by":"crossref","unstructured":"Chen, M. et al. Senecavirus A induces mitophagy to promote self-replication through direct interaction of 2C protein with K27-linked ubiquitinated TUFM catalyzed by RNF185. Autophagy, 20, 1286\u20131313 (2024).","DOI":"10.1080\/15548627.2023.2293442"},{"key":"10070_CR45","doi-asserted-by":"publisher","first-page":"e1006264","DOI":"10.1371\/journal.ppat.1006264","volume":"13","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. PLoS Pathog. 13, e1006264 (2017).","journal-title":"PLoS Pathog."},{"key":"10070_CR46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.immuni.2014.11.011","volume":"41","author":"Q Wang","year":"2014","unstructured":"Wang, Q. et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 41, 919\u2013933 (2014).","journal-title":"Immunity"},{"key":"10070_CR47","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1080\/15548627.2022.2139921","volume":"19","author":"Z Ma","year":"2023","unstructured":"Ma, Z. et al. Tegument protein UL21 of alpha-herpesvirus inhibits the innate immunity by triggering CGAS degradation through TOLLIP-mediated selective autophagy. Autophagy 19, 1512\u20131532 (2023).","journal-title":"Autophagy"},{"key":"10070_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105395","volume":"299","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Smurf1 polyubiquitinates on K285\/K282 of the kinases Mst1\/2 to attenuate their tumor-suppressor functions. J. Biol. Chem. 299, 105395 (2023).","journal-title":"J. Biol. Chem."},{"key":"10070_CR49","doi-asserted-by":"publisher","first-page":"e00321","DOI":"10.1128\/JVI.00321-18","volume":"92","author":"B Xue","year":"2018","unstructured":"Xue, B. et al. TRIM21 Promotes Innate Immune Response to RNA Viral Infection through Lys27-Linked Polyubiquitination of MAVS. J. Virol. 92, e00321\u201318 (2018).","journal-title":"J. Virol."},{"key":"10070_CR50","doi-asserted-by":"publisher","first-page":"113733","DOI":"10.1016\/j.yexcr.2023.113733","volume":"431","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Lin, B., Yang, S. & Huang, J. IRF1 suppresses colon cancer proliferation by reducing SPI1-mediated transcriptional activation of GPX4 and promoting ferroptosis. Exp. Cell Res. 431, 113733 (2023).","journal-title":"Exp. Cell Res"},{"key":"10070_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/15384047.2015.1046646","volume":"16","author":"MJ Armstrong","year":"2015","unstructured":"Armstrong, M. J. et al. IRF-1 inhibits NF-\u03baB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition. Cancer Biol. Ther. 16, 1029\u20131041 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"10070_CR52","doi-asserted-by":"publisher","first-page":"e136720","DOI":"10.1172\/jci.insight.136720","volume":"5","author":"R Karki","year":"2020","unstructured":"Karki, R. et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI Insight 5, e136720 (2020).","journal-title":"JCI Insight"},{"key":"10070_CR53","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s43018-023-00522-1","volume":"4","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat. Cancer 4, 382\u2013400 (2023).","journal-title":"Nat. Cancer"},{"key":"10070_CR54","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi, M. R. & Merlino, G. The two faces of interferon-\u03b3 in cancer. Clin. Cancer Res. 17, 6118\u20136124 (2011).","journal-title":"Clin. Cancer Res"},{"key":"10070_CR55","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl. Acad. Sci. USA. 116, 22699\u201322709 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10070_CR56","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson, D. J. et al. Pembrolizumab Plus Ipilimumab Following Anti-PD-1\/L1 Failure in Melanoma. J. Clin. Oncol. 39, 2647\u20132655 (2021).","journal-title":"J. Clin. Oncol."},{"key":"10070_CR57","doi-asserted-by":"publisher","first-page":"e154754","DOI":"10.1172\/JCI154754","volume":"133","author":"L Ding","year":"2023","unstructured":"Ding, L. et al. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J. Clin. Invest 133, e154754 (2023).","journal-title":"J. Clin. Invest"},{"key":"10070_CR58","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha, J. H. et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol. Cell 71, 606\u2013620.e607 (2018).","journal-title":"Mol. Cell"},{"key":"10070_CR59","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1007\/s11033-020-05669-z","volume":"47","author":"BH Kiani","year":"2020","unstructured":"Kiani, B. H. et al. Artemisinin and its derivatives: a promising cancer therapy. Mol. Biol. Rep. 47, 6321\u20136336 (2020).","journal-title":"Mol. Biol. Rep."},{"key":"10070_CR60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1517\/14728222.2013.733001","volume":"17","author":"S Thomas","year":"2013","unstructured":"Thomas, S. et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin. Ther. Targets 17, 61\u201375 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"10070_CR61","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00432-014-1771-7","volume":"140","author":"P Li","year":"2014","unstructured":"Li, P. et al. Synergic effects of artemisinin and resveratrol in cancer cells. J. Cancer Res Clin. Oncol. 140, 2065\u20132075 (2014).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10070_CR62","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013d1217 (2019).","journal-title":"Nucleic Acids Res"},{"key":"10070_CR63","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 50, D1522\u2013d1527 (2022).","journal-title":"Nucleic Acids Res"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10070-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10070-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10070-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:04:40Z","timestamp":1782176680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10070-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10070"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10070-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"856"}}